Tech Company Financing Transactions
Versanis Bio Funding Round
Atlas Venture, Medicxi Ventures and Aditum Bio participated in a $70 million Series A venture round for Versanis Bio. The round was announced on 9/1/2021.
Transaction Overview
Company Name
Announced On
9/1/2021
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1111 Bdwy. 1300
Oakland, CA 94607
USA
Oakland, CA 94607
USA
Phone
Website
Email Address
Overview
Versanis Bio was established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lloyd Klickstein
Browse more venture capital transactions:
Prev: 9/1/2021: Owner.com venture capital transaction
Next: 9/1/2021: OneRail venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs